In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Kepivance, Stemgen, & Kineret deal for Amgen, Biovitrum

Executive Summary

Biovitrum AB has outright acquired Kepivance (palifermin) and Stemgen (ancestim) from Amgen as well as gained an exclusive global license to Amgen's Kineret (anakinra). Biovitrum has purchased an inventory of the three products.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Product Purchase
    • Includes Equity
    • Intra-Biotech Deal
    • Reverse Licensing

Related Companies